"COVID-19 associated divergent thrombotic thrombocytopenic purpura (TTP) syndromes reported so far, five and counting": Classification and possible therapeutic options. Issue 219 (November 2022)

• Record Type: Journal Article
• Authors: Mir, Tajamul H.
• Is Part Of: Thrombosis research. Issue 219(2022)
• Page Start: 86
• Page End: 88
• Publication Date: 2022-11
• Subjects: TMA Thrombotic microangiopathy -- TTP Thrombotic thrombocytopenic purpura -- HUS Hemolytic uremic syndrome -- iTTP Immune thrombotic thrombocytopenic purpura -- ADAMTS-13 A disintegrin and metalloproteinase with thrombospondin type 1 motif member 13 -- rADAMTS-13 Recombinant ADAMTS-13 -- vWF von Willebrand factor -- ULVWF Ultra-large von Willebrand factor -- VITT Vaccine-induced immune thrombotic thrombocytopenia -- VI-iTTP Vaccine induced immune thrombotic thrombocytopenic purpura -- PEX Plasma exchange; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2022.09.016
• Languages: English
• ISSNs: 0049-3848

Abstract

Highlights: The thrombotic complications of Covid 19 have posed a major therapeutic challenge to the clinician especially in critically ill. Besides the classic COVID-19 coagulopathy, a few cases of the thrombotic microangiopathy thrombotic thrombocytopenic purpura (TTP) have been reported as well following severe SARS CoV-2 infection. TTP, in the light of COVID-19, seems to be a mixed bag of different syndromes rather than a single entity requiring intense research, understanding, and timely recognition of these syndromes. A germane therapeutic approach could positively influence the outcome in these COVID-19 associated TTP syndeomes.